Yemen Health Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Yemen Health Report.

Press releases published on September 29, 2026

Sep. 29, 2026

Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

Indeterminate GlobeNewswire

Sep. 29, 2026

Precision Optics to Participate in the Lytham Partners Fall 2026 Investor Conference

Indeterminate GlobeNewswire

Sep. 29, 2026

IMUNON Converts $1.2 Million of Debt-to-Equity

Indeterminate GlobeNewswire

Sep. 29, 2026

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

Indeterminate GlobeNewswire

Sep. 29, 2026

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

Indeterminate GlobeNewswire

Sep. 29, 2026

Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia

Indeterminate GlobeNewswire

Sep. 29, 2026

Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

Indeterminate GlobeNewswire

Sep. 29, 2026

uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression

Indeterminate GlobeNewswire

Sep. 29, 2026

Kraig Biocraft Laboratories Ships its First Commercial Spider Silk Yarn Order for Performance Sports Brand

Indeterminate GlobeNewswire

Sep. 29, 2026

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

Indeterminate GlobeNewswire

Sep. 29, 2026

Boehringer Ingelheim investments into sustainability-related programs and health partnerships to reach EUR 500 million

Indeterminate GlobeNewswire

Sep. 29, 2026

PolarityBio’s Phase 3 COVER DFUS II Trial Selected for First-to-Podium Presentation at SAWC Fall 2026

Indeterminate GlobeNewswire

Sep. 29, 2026

Ocugen to Participate in Upcoming October Investor and Industry Conferences

Indeterminate GlobeNewswire

Sep. 29, 2026

BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

Indeterminate GlobeNewswire

Sep. 29, 2026

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

Indeterminate GlobeNewswire

Sep. 29, 2026

Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites

Indeterminate GlobeNewswire

Sep. 29, 2026

Why Weight Loss Plateaus Happen: 5 Metabolic Causes

Indeterminate GlobeNewswire

Sep. 29, 2026

ABBYY Appoints Paula Sanders to Chief Customer Experience Officer, Providing Customers a Single, End-to-End Experience

Indeterminate GlobeNewswire

Sep. 29, 2026

NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer

Indeterminate GlobeNewswire

Sep. 29, 2026

Cascade Prodrug Inc. Appoints Kenneth Mandell, M.D., Ph.D. to Board of Directors

Indeterminate GlobeNewswire